United Guardian vs cbdMD
UG and YCBD side by side, both in soap, detergents, and cleaning preparations; perfumes, cosmetics, and other toilet preparations. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How UG and YCBD compare
United Guardian is the larger company, worth 9.1 times as much as cbdMD ($37.1M against $4.1M).
cbdMD grew revenue faster over the last twelve months (10.0% versus 3.2% for United Guardian).
United Guardian keeps more of each dollar of sales as profit, with a net margin of 22.0% compared with −13.8% at cbdMD.
United Guardian pays a dividend yielding 6.8%; cbdMD does not pay one.
United Guardian scores higher on the StockData Score (18 against 10 for cbdMD), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | UG | YCBD |
|---|---|---|
| Size and price | ||
| Market cap | $37.1M | $4.1M |
| Share price | $8.08 | $0.363 |
| Change, 1 year | 31.0% | −50.8% |
| Change, 5 years | −49.4% | −99.9% |
| Beta (5Y) | 0.68 | 2.28 |
| Employees | 25 | 42 |
| StockData Score | ||
| Total score | 18 (better) | 10 |
| Valuation score | 4 (better) | 3 |
| Growth score | 0 | 1 (better) |
| Performance score | 4 (better) | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 15.0× | – |
| P/S | 3.3× | 0.2× (better) |
| P/B | 3.2× | 0.5× (better) |
| EV/EBITDA | 11.2× | – |
| P/FCF | 10.9× | – |
| FCF yield | 9.2% (better) | −59.2% |
| Fair value | $10.21 | $2.01 |
| Margin of safety | 20.9% | 82.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 3.2% | 10.0% (better) |
| Revenue growth, 5Y average | −0.82% (better) | −14.5% |
| Net income growth (TTM) | −3.6% | – |
| EPS growth (TTM) | −3.6% | – |
| Profitability | ||
| Gross margin | 46.9% | 57.7% (better) |
| Operating margin | 20.8% (better) | −13.9% |
| Net margin | 22.0% (better) | −13.8% |
| FCF margin | 30.3% (better) | −11.5% |
| Return on equity | 21.4% (better) | −40.3% |
| Return on invested capital | 73.2% (better) | −41.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 7.32 (better) | 2.50 |
| Altman Z-score | 14.87 (better) | −17.59 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 6.8% | – |
| Payout ratio | 93.2% | – |
| Shareholder yield | 6.8% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 19.2% | 8.2% |
| Held by insiders | 52.3% | 34.6% |
| Insider net buying, 12 months | – | −$1.3M |
| Short interest, % of float | 0.39% | 6.6% |
Go deeper
- UG stock overview
- UG income statement
- UG valuation and score
- YCBD stock overview
- YCBD income statement
- YCBD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.